AnalystsEvan David Seigerman
Evan David Seigerman's Stock Forecasts

Analyst Ranking
Top 21%
#1117 out of 5346 analysts
Average Return
+8.87%
Win Rate
58%33 out of 57
Risk vs Reward
Poor
Good

Evan David Seigerman's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Candel Therapeutics IncCADL
+568.75%$1.60$10.70
2023-05-15 -
2024-05-14
Buy
Morphic Holding IncMORF
+147.53%$22.49$55.67
2023-09-28 -
2024-07-09
Buy
Eli Lilly & CoLLY
+81.93%$306.82$558.19
2022-09-06 -
2023-09-05
Buy
Merus NvMRUS
+63.22%$55.14$90.00
2025-05-23 -
2025-12-29
Buy
Neurogene IncNGNE
+44.91%$18.55$26.88
2025-05-20 -
2026-05-19
Buy

Evan David Seigerman's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Amgen IncAMGN
6Buy$450.00+9.50%Maintains
3 days ago
Acadia Pharmaceuticals IncACAD
3Buy$36.00+23.25%Maintains
18 days ago
Pfizer IncPFE
5Buy$30.00+12.11%Maintains
a month ago
Merck & Co IncMRK
6Buy$142.00+10.44%Maintains
a month ago
Abbvie IncABBV
9Buy$300.00+21.93%Maintains
a month ago
Regeneron Pharmaceuticals IncREGN
10Buy$730.00-6.93%Maintains
3 months ago
Disc Medicine IncIRON
2Buy$100.00+29.13%Maintains
6 months ago
Novo Nordisk A SNVO
8Hold$46.00-2.67%Maintains
8 months ago
Replimune Group IncREPL
5Hold$11.00-8.79%Upgrades
9 months ago
Neurogene IncNGNE
2Buy$26.00N/AMaintains
a year ago
Merus NvMRUS
1Buy$110.00N/AMaintains
a year ago
Arvinas IncARVN
1Buy$10.00N/AMaintains
a year ago
Morphic Holding IncMORF
3Hold$57.00N/ADowngrades
2 years ago
Structure Therapeutics IncGPCR
2Buy$100.00N/AMaintains
2 years ago
Mirati Therapeutics IncMRTX
4Hold$72.00N/AMaintains
3 years ago
Candel Therapeutics IncCADL
1Buy$3.00N/AMaintains
3 years ago
Eli Lilly & CoLLY
1Buy$396.00N/AMaintains
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.